NCT01707004 - Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2013

Primary Completion Date

July 22, 2017

Study Completion Date

October 7, 2017

Conditions

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Interventions

DRUG

decitabine

Given IV

DRUG

fludarabine phosphate

Given IV

DRUG

busulfan

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

tacrolimus

Given PO or IV

DRUG

mycophenolate mofetil

Given PO

BIOLOGICAL

filgrastim

Given SC

RADIATION

total-body irradiation

Undergo total-body irradiation

PROCEDURE

allogeneic bone marrow transplantation

Undergo allogeneic bone marrow transplantation

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER